Mithramycin nano-particle suspension and preparation method thereof

Inactive Publication Date: 2017-09-15
MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the clinical use of shimmermycin in tumor therapy requires

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mithramycin nano-particle suspension and preparation method thereof
  • Mithramycin nano-particle suspension and preparation method thereof
  • Mithramycin nano-particle suspension and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Example 1: Preparation of a suspension of scintillation nanoparticles

[0109] The basic process of preparing scintilaginous nanoparticles by emulsification solvent evaporation method is shown in the appendix. figure 1 .

[0110] The implementation steps of this embodiment are as follows:

[0111] A. Preparation of diblock copolymer solution

[0112] The mPEG-PLGA diblock copolymer (PEG molecular weight 5000Da; PLGA molecular weight 15000Da; lactic acid and glycolic acid molar ratio: 50 / 50) sold by Jinan Daigang Bioengineering Co., Ltd. was dissolved in ethyl acetate solvent to obtain a concentration of 30 mg / mL diblock copolymer ethyl acetate solution;

[0113] B, the preparation of the organic phase of fucoidin

[0114] To the ethyl acetate solution of the diblock copolymer described above was added the diblock copolymer in the ratio 1:2.2 of the ethyl acetate solution in milliliters to the mithramycin in milligrams, marketed by Sigma-Aldrich under the trade nam...

Embodiment 2

[0123] Example 2: Preparation of a Pseudomycin Nanoparticle Suspension

[0124] The implementation steps of this embodiment are as follows:

[0125] A. Preparation of diblock copolymer solution

[0126] The PEG-PLLA diblock copolymer (PEG molecular weight 3000Da; PLLA molecular weight 15000Da) sold by Jinan Daigang Bioengineering Co., Ltd. was dissolved in dichloromethane solvent to obtain a diblock copolymer dichloromethane with a concentration of 40 mg / mL. solution;

[0127] B, the preparation of the organic phase of fucoidin

[0128] In accordance with the ratio of dichloromethane solution in milliliters to 1:1.0 in milligrams of scintilbomycin SK, the scintilbomycin SK reported by the document JAmChem Soc. 2003 May 14; 125(19): 5745-53 was added to the above Diblock copolymer in dichloromethane solution, shake and dissolve, obtain a kind of organic phase that contains brightmycin SK;

[0129] C. Preparation of emulsifier solution

[0130] The emulsifier PVA is dissolv...

Embodiment 3

[0137] Example 3: Preparation of a Pseudomycin Nanoparticle Suspension

[0138] The implementation steps of this embodiment are as follows:

[0139] A. Preparation of diblock copolymer solution

[0140] The PEG-PDLA diblock copolymer (PEG molecular weight 5000Da; PDLA molecular weight 20000Da) sold by Jinan Daigang Bioengineering Co., Ltd. was dissolved in chloroform solvent to obtain a diblock copolymer chloroform with a concentration of 34mg / mL. solution;

[0141] B, the preparation of the organic phase of fucoidin

[0142] According to the ratio 1:1.6 of chloroform solution in milliliters to the Spotomycin SDK in mg, the Spotsomycin SDK reported by the document JAmChem Soc. 2003 May 14; 125(19): 5745-53 was added to the above-mentioned dimeric In the chloroform solution of the segmented copolymer, vibrating and dissolving to obtain an organic phase containing the Spotomycin SDK;

[0143] C. Preparation of emulsifier solution

[0144] Dissolving the emulsifier sodium ch...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Surface chargeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
The average particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a mithramycin nano-particle suspension and a preparation method thereof. The preparation method comprises the following steps: preparation of a diblock copolymer solution; preparation of an organic phase of mithramycin; preparation of an emulsifier solution; mixing and aftertreatment; etc. A mithramycin nano-particle prepared in the invention can retain the pharmacological activity of mithramycin; materials used in the invention are biocompatible materials, so the mithramycin nano-particle has the characteristic of application security and has good application prospect; meanwhile, the mithramycin nano-particle can be effectively enriched in the part of a transplanted tumor of a naked mouse and presents substantial treatment effect on transplanted tumors of human pancreatic cancer cells BxPC-3 in naked mice.

Description

【Technical field】 [0001] The invention belongs to the technical field of drug delivery. More specifically, the present invention relates to a kind of incandescent nanoparticle suspension, and also relates to a preparation method of the incandescent nanoparticle suspension. 【Background technique】 [0002] MithramycinA (MIT), also known as prukamycin, is a naturally occurring polyketide antitumor antibiotic belonging to the chloramylic acid family. Since it was approved for clinical application, it has been used as a chemotherapeutic drug to treat malignant tumors such as testicular embryonic carcinoma and glioma. Glaxinomycin can bind to the minor groove of the GC-rich region on DNA, and the main mechanism of action is to competitively inhibit the binding of transcription factor Sp1 to gene regulatory elements, thereby affecting the formation of DNA-protein complexes and regulating related genes. expression. Sp1 is a transcription factor with a zinc finger structure, which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/107A61K47/34A61K31/704A61P35/00
CPCA61K9/1075A61K31/704A61K47/34
Inventor 刘旭杰李良甄永苏刘秀均赵春燕王瑞琪
Owner MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap